Of the tracked stories, 1 of 2 also mention Activest Wealth Management, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 5.6. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Jane Street Group LLC
Of the tracked stories, 1 of 2 also mention Activest Wealth Management, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 5.6. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 2 original sources each against 2.2 for the same window. Jane Street Group LLC appears in 2 tracked Healthcare stories published from August 13, 2026 through August 17, 2026.
Stories tracked
2
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 47 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Jane Street Group LLC. Shared-story counts are live from our verified record — not editorial picks.
A wave of institutional accumulation in STERIS plc — including a 32.3% Goldman Sachs position increase and a new $1.03 million Stoneridge stake in Q2 2026 — signals confidence in the medical equipment provider's infection-prevention franchise. With institutions now holding 94.69% of shares and the company maintaining a 0.23 debt-to-equity ratio, STERIS appears positioned to absorb hospital capital-expenditure cycles. A modest June insider sale by director Richard C. Breeden at $209.51 is a minor contrarian signal in an otherwise bullish institutional pattern.
Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
Jane Street Group LLC is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
